Upstream and downstream solutions for AAV manufacturingPublished: August 19, 2019
Jessica de Rooij, Jessica DeConto, Gicell Schaenzler, Darren Bauer, Kyle Barre, Meg Duskin, Abhijeet Kohli & Kim Watanabe
VECTOR CHANNEL: SUSPENSION CULTURE SYSTEMS
With the advancement of gene delivery vectors and gene editing technologies, cell and gene therapies are a very real solution to many previously untreatable or difficult to treat diseases. With this heightened interest in cell and gene therapies, the need for powerful, cost-effective, and scalable methods to deliver these therapies has intensified. Whilst here are a number of non-viral methods for delivery of gene therapies already being utilized, viral delivery remains the most commonly employed method. This article discusses the current AAV manufacuring workflows and identifies opportunities, both upstream and downstream, for process optimisation to support the scalable manufacture of viral vectors to support the increasing demand.DOI: 10.18609/cgti.2019.110
Submitted for review: June 24, 2019
Citation: Cell & Gene Therapy Insights 2019; 5(Suppl. 5), 1017-1029.
I agree for the Thermo Fisher Scientific group (thermofisher.com/legalentities) to contact me by e-mail and telephone to inform me of events, products, services and promotions offered in connection with the brands Thermo Scientific™, Applied Biosystems™, Invitrogen™, Gibco™, Ion Torrent™, Unity Lab Services™, Fisher Scientific™. I can withdraw my consent and unsubscribe at any time by e-mailing firstname.lastname@example.org.